Factors driving decisions in the use of HIV pre-exposure prophylaxis: a real-world study in the United States.

IF 1.7 4区 医学 Q3 INFECTIOUS DISEASES HIV Research & Clinical Practice Pub Date : 2024-12-01 Epub Date: 2024-08-08 DOI:10.1080/25787489.2024.2382552
Yohance Whiteside, Abigail McMillan, Fritha Hennessy, Phoebe Salmon, Tim Holbrook, Bekana K Tadese
{"title":"Factors driving decisions in the use of HIV pre-exposure prophylaxis: a real-world study in the United States.","authors":"Yohance Whiteside, Abigail McMillan, Fritha Hennessy, Phoebe Salmon, Tim Holbrook, Bekana K Tadese","doi":"10.1080/25787489.2024.2382552","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Uptake of pre-exposure prophylaxis (PrEP) in the United States (US) remains below target, despite reported high efficacy in prevention of HIV infection and being considered as a strategy for ending new HIV transmissions. Here, we sought to investigate drivers for PrEP use and barriers to increased uptake using real-world data. <b>Methods:</b> Data were drawn from the Adelphi PrEP Disease Specific Programme<sup>™</sup>, a cross-sectional survey of PrEP users and PrEP non-users at risk for HIV and their physicians in the US between August 2021 and March 2022. Physicians reported demographic data, clinical characteristics, and motivations for prescribing PrEP. PrEP users and non-users reported reasons for or against PrEP use, respectively. Bivariate analyses were performed to compare characteris tics of users and non-users. <b>Results:</b> In total, 61 physicians reported data on 480 PrEP users and 121 non-users. Mean ± standard deviation of age of users and non-users was 35.3 ± 10.8 and 32.5 ± 10.8 years, respectively. Majority were male and men who have sex with men. Overall, 90.0% of users were taking PrEP daily and reported fear of contracting HIV (79.0%) and having at-risk behaviors as the main drivers of PrEP usage. About half of non-users (49.0%) were reported by physicians as choosing not to start PrEP due to not wanting long-term medication. PrEP stigma was a concern for both users (50.0%) and non-users (65.0%). More than half felt that remembering to take PrEP (57.0%) and the required level of monitoring (63.0%) were burdensome. <b>Conclusions:</b> Almost half of people at risk for HIV were not taking PrEP due to not wanting long-term daily medication and about half of current PrEP users were not completely adherent. The most common reason for suboptimal adherence was forgetting to take medication. This study highlighted drivers for PrEP uptake from physician, PrEP user, and non-user perspectives as well as the attributes needed in PrEP products to aid increased PrEP uptake.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"25 1","pages":"2382552"},"PeriodicalIF":1.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Research & Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/25787489.2024.2382552","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Uptake of pre-exposure prophylaxis (PrEP) in the United States (US) remains below target, despite reported high efficacy in prevention of HIV infection and being considered as a strategy for ending new HIV transmissions. Here, we sought to investigate drivers for PrEP use and barriers to increased uptake using real-world data. Methods: Data were drawn from the Adelphi PrEP Disease Specific Programme, a cross-sectional survey of PrEP users and PrEP non-users at risk for HIV and their physicians in the US between August 2021 and March 2022. Physicians reported demographic data, clinical characteristics, and motivations for prescribing PrEP. PrEP users and non-users reported reasons for or against PrEP use, respectively. Bivariate analyses were performed to compare characteris tics of users and non-users. Results: In total, 61 physicians reported data on 480 PrEP users and 121 non-users. Mean ± standard deviation of age of users and non-users was 35.3 ± 10.8 and 32.5 ± 10.8 years, respectively. Majority were male and men who have sex with men. Overall, 90.0% of users were taking PrEP daily and reported fear of contracting HIV (79.0%) and having at-risk behaviors as the main drivers of PrEP usage. About half of non-users (49.0%) were reported by physicians as choosing not to start PrEP due to not wanting long-term medication. PrEP stigma was a concern for both users (50.0%) and non-users (65.0%). More than half felt that remembering to take PrEP (57.0%) and the required level of monitoring (63.0%) were burdensome. Conclusions: Almost half of people at risk for HIV were not taking PrEP due to not wanting long-term daily medication and about half of current PrEP users were not completely adherent. The most common reason for suboptimal adherence was forgetting to take medication. This study highlighted drivers for PrEP uptake from physician, PrEP user, and non-user perspectives as well as the attributes needed in PrEP products to aid increased PrEP uptake.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
驱动使用艾滋病暴露前预防决策的因素:美国真实世界研究。
背景:尽管据报道暴露前预防疗法(PrEP)在预防艾滋病病毒感染方面具有很高的疗效,并被认为是杜绝艾滋病病毒新传播的一种策略,但其在美国的使用率仍低于目标值。在此,我们试图利用真实世界的数据来调查使用 PrEP 的驱动因素以及提高使用率的障碍。研究方法数据来自 Adelphi PrEP Disease Specific Programme™(阿德尔菲 PrEP 特定疾病计划™),该计划是在 2021 年 8 月至 2022 年 3 月期间对美国的 PrEP 使用者和非 PrEP 使用者及其医生进行的横断面调查。医生报告了人口统计学数据、临床特征以及开具 PrEP 处方的动机。PrEP 使用者和非使用者分别报告了使用或反对使用 PrEP 的原因。通过双变量分析比较了使用者和非使用者的特征。结果:共有 61 名医生报告了 480 名 PrEP 使用者和 121 名非使用者的数据。使用者和非使用者的平均年龄(标准差)分别为 35.3 ± 10.8 岁和 32.5 ± 10.8 岁。大多数为男性和男男性行为者。总体而言,90.0%的使用者每天服用 PrEP,他们表示害怕感染艾滋病毒(79.0%)和有高危行为是使用 PrEP 的主要原因。据医生报告,约有一半的非使用者(49.0%)因不希望长期服药而选择不开始使用 PrEP。PrEP 的耻辱感是使用者(50.0%)和非使用者(65.0%)都担心的问题。一半以上的人认为,记住服用 PrEP(57.0%)和所需的监测水平(63.0%)是一种负担。结论:近一半的艾滋病病毒感染高危人群由于不希望每天长期服药而没有服用 PrEP,大约一半的 PrEP 现有使用者没有完全坚持服药。未达到最佳依从性的最常见原因是忘记服药。这项研究从医生、PrEP 使用者和非使用者的角度强调了 PrEP 吸纳的驱动因素,以及 PrEP 产品所需的属性,以帮助提高 PrEP 的吸纳率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.90
自引率
6.20%
发文量
15
期刊最新文献
A closer look: factors impacting HIV durable viral suppression among a cohort of clinic attendees in Trinidad & Tobago. Evaluation of the effect of 48 weeks of BIC/F/TAF and DRV/c/F/TAF on platelet function in the context of rapid ART start. 'It is scary to pause treatment': perspectives on HIV cure-related research and analytical treatment interruptions from women diagnosed during acute HIV in Durban, South Africa. Impacts of a multipronged initiative with community HIV clinics to support retention and re-engagement in HIV care. Heterogeneity of provider preferences for HIV Care Coordination Program features: latent class analysis of a discrete choice experiment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1